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Abstract
Background: Genome-wide association studies (GWAS) of single nucleotide polymorphisms (SNPs) have been successful
in identifying loci contributing genetic effects to a wide range of complex human diseases and quantitative traits. The
traditional approach to GWAS analysis is to consider each phenotype separately, despite the fact that many diseases and
quantitative traits are correlated with each other, and often measured in the same sample of individuals. Multivariate
analyses of correlated phenotypes have been demonstrated, by simulation, to increase power to detect association with
SNPs, and thus may enable improved detection of novel loci contributing to diseases and quantitative traits.
Results: We have developed the SCOPA software to enable GWAS analysis of multiple correlated phenotypes. The
software implements “reverse regression” methodology, which treats the genotype of an individual at a SNP as the
outcome and the phenotypes as predictors in a general linear model. SCOPA can be applied to quantitative traits and
categorical phenotypes, and can accommodate imputed genotypes under a dosage model. The accompanying META-
SCOPA software enables meta-analysis of association summary statistics from SCOPA across GWAS. Application of SCOPA
to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and body mass index, and subsequent meta-
analysis with META-SCOPA, highlighted stronger association signals than univariate phenotype analysis at established
lipid and obesity loci. The META-SCOPA meta-analysis also revealed a novel signal of association at genome-wide
significance for triglycerides mapping to GPC5 (lead SNP rs71427535, p = 1.1x10−8), which has not been reported in
previous large-scale GWAS of lipid traits.
Conclusions: The SCOPA and META-SCOPA software enable discovery and dissection of multiple phenotype
association signals through implementation of a powerful reverse regression approach.
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Background
In the past decade, genome-wide association studies
(GWAS) of single nucleotide polymorphisms (SNPs)
have proven to be successful in identifying loci contrib-
uting genetic effects to a wide range of complex human
traits, including susceptibility to diseases [1]. Interest-
ingly, many of these loci harbour SNPs that are associ-
ated with multiple phenotypes, some of which are
correlated with each other (such as serum lipid concen-
trations [2]) or share underlying pathophysiology (such
as chronic inflammatory diseases [3]), whilst others are
epidemiologically unrelated.
The observation of multiple phenotype association at
the same locus can occur as a result of pleiotropy [4].
Biological pleiotropy describes the scenario in which
SNPs in the same gene are directly causal for multiple
phenotypes. Biological pleiotropy can be considered: (i)
at the “allelic level”, where the causal variant is the same
for all phenotypes; (ii) due to “co-localisation”, for which
the causal variants are not the same for all phenotypes,
but are correlated with each other (i.e. in linkage dis-
equilibrium); or (iii) at the “genic level”, where the causal
variants are not the same for all phenotypes, and are un-
correlated with each other. Mediated pleiotropy occurs
when a SNP is directly causal for one phenotype, which
is in turn correlated, epidemiologically, with others.
Spurious pleiotropy refers to multi-phenotype associa-
tions that do not reflect shared underlying genetic path-
ways, and can occur when causal variants act through
different genes at the same locus, as a result of con-
founding that is not adequately accounted for in the
analysis, or due to misclassification or ascertainment
bias in disease cases.
The traditional approach to the analysis of GWAS is
to consider each phenotype separately (i.e. univariate),
despite the fact that many diseases and quantitative
traits are correlated with each other, and often measured
in the same sample of individuals. However, under these
circumstances, there may be increased power to detect
novel loci associated with multiple phenotypes through
multivariate analyses [5]. A wide range of methods have
been proposed, including multivariate analysis of variance
[6], dimension reduction [7, 8], generalised estimating
equations [9], Bayesian networks [10], and non-parametric
approaches [11]. The most suitable approach will often
depend on study design because, for example, methods
may be restricted to the analysis of quantitative traits, or
cannot accommodate covariates.
One of the most flexible multivariate methods for
multiple phenotype analysis uses “reverse regression”
techniques. With this approach, phenotypes are used as
predictors of genotype at a SNP in an ordinal regression
model [12]. Unlike multivariate analysis of variance, as
implemented in the MAGWAS software [6], reverse
regression has the advantage that it can simultaneously
incorporate both quantitative traits and categorical phe-
notypes in the same model. Simulations have also dem-
onstrated that this approach has a dramatic increase in
power over univariate analyses in many scenarios, whilst
controlling false positive error rates [12]. Reverse regres-
sion has the disadvantage, however, that model param-
eter estimates cannot be directly interpreted in terms of
the effect of a SNP on each phenotype. The reverse re-
gression approach has been previously implemented in
the MultiPhen package: https://cran.r-project.org/web/
packages/MultiPhen/index.html.
Here we implement a reverse regression model for
multiple correlated phenotypes in SCOPA (Software for
COrrelated Phenotype Analysis) that has a number of
key advantages over MultiPhen. First, the software can
accommodate directly typed and imputed SNPs (under
an additive dosage model), appropriately accounting for
uncertainty in the imputation in the downstream asso-
ciation analysis. Second, dissection of multivariate asso-
ciation signals is achieved through model selection to
determine which phenotypes are jointly associated with
the SNP. Third, SCOPA association summary statistics
can also be aggregated across GWAS through fixed-
effects meta-analysis, implemented in META-SCOPA,
enabling application of reverse regression in large-
scale international consortia efforts where individual-
level genotype are phenotype data cannot be shared
between studies.
To demonstrate the power and utility of this approach,
we apply the software to two GWAS of high— and
low-density lipoprotein (HDL and LDL) cholesterol,
triglycerides (TG) and body mass index (BMI), and
evaluate association signals in established lipid and
obesity loci.
Implementation
Reverse regression model of multiple correlated
phenotypes
Consider a sample of unrelated individuals with J pheno-
types denoted by y1, y2, …, yJ. At a SNP, we denote the
genotype of the ith individual by Gi, coded under an
additive model in the number of minor alleles (dosage
after imputation). Under linear reverse regression, we
model the genotype as a function of the observed phe-
notypes, such that
Gi ¼ αþ
X
j
βjyij þ i: ð1Þ
In this expression, βj denotes the effect of the jth
phenotype on genotype at the SNP, and ϵi ~N(0, σ
2),
where σ2 is the residual variance. A joint test of associ-
ation of the SNP with the phenotypes, with J degrees of
freedom is constructed by comparing the maximised
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log-likelihood of the unconstrained model (1), with that
obtained under the null model, for which β = 0. The max-
imum likelihood estimate, β^j, of the effect of the jth pheno-
type is adjusted for all other traits included in the reverse
regression model, and thus implicitly accounts for the cor-
relation between them.
It is important to account for potential confounding, for
example arising as a result of population structure. We
therefore recommend that phenotypes are replaced by re-
siduals after adjustment for “general” confounders, such
as age, sex and principal components to account for popu-
lation structure, as covariates in a generalised linear mod-
elling framework. However, where a potential confounder
might share genetic effects with the phenotypes under
investigation, such as body-mass index in the analysis of
waist-hip ratio, we would recommend including this as an
additional variable in the reverse regression model.
Dissection of multiple phenotype association signals
For SNPs attaining genome-wide significant evidence of
association (p <5×10−8) with the phenotypes, it may be
of interest to further dissect the signal through model
selection. We obtain a maximised log-likelihood of the
model (1) for each possible subset of phenotypes (so that
βj = 0 if the jth phenotype is excluded from the model).
We then determine the “best” subset of phenotypes as-
sociated with the SNP as the model with minimum
Bayesian information criterion (BIC).
Meta-analysis
Consider K GWAS of the same set of correlated pheno-
types. At a SNP, we denote the maximum likelihood esti-
mates of the effect of the phenotypes from the kth
GWAS by β^k , with corresponding variance-covariance
matrix Vk. Association summary statistics are then ag-
gregated across studies using the method for the synthe-
sis of regression slopes [13]. The BIC for each model for
a SNP can also be aggregated across GWAS to enable
dissection of the association signal after meta-analysis.
Genomic control
To correct for residual population structure within and
between GWAS, which is not accounted for in study-
level association analyses, we calculate the genomic
control inflation factor, λ, on the basis of J degrees of
freedom, one for each phenotype [14]. The inflation
factor is calculated at the study level (denoted λk for the
kth GWAS) and after meta-analysis (denoted λMA), en-
abling “double” genomic control correction. Elements of
the variance-covariance matrix of the kth study, Vk, are
inflated by λk, unless λk <1. Similarly, elements of the
variance-covariance matrix after meta-analysis are in-
flated by λMA, unless λMA <1.
SCOPA and META-SCOPA
Genome-wide study-level multiple phenotype analysis,
including dissection of association signals, has been im-
plemented in SCOPA. The software requires specifica-
tion of input genotype and sample files, and a list of
phenotypes to be included in the analysis. SCOPA
includes options to enable filtering on the basis of im-
putation quality (info score) [15], to output the variance-
covariance matrix and phenotype effects (with standard
errors) for each SNP, and to investigate association with
all possible subsets of phenotypes using BIC.
Genome-wide meta-analysis has then been imple-
mented in META-SCOPA. The software requires specifi-
cation of a list of SCOPA output files representing
studies to be included in the meta-analysis. META-
SCOPA includes options to enable genomic control cor-
rection (at the study level and/or after meta-analysis),
and filtering of SNPs on the basis of minor allele fre-
quency (MAF) and imputation quality.
Required file formats
SCOPA requires genotype and phenotype data in GEN/
SAMPLE file format utilised by IMPUTE and SNPTEST
[15–17]. This format accommodates imputed genotype
data in the GEN file and multiple phenotypes in the SAM-
PLE file. Full details of the file formats can be found
at: http://www.stats.ox.ac.uk/~marchini/software/gwas/
file_format.html. Conversion to GEN/SAMPLE files
from other formats for genotype/phenotype data can be
performed using GTOOL: http://www.well.ox.ac.uk/
~cfreeman/software/gwas/gtool.html.
Results and discussion
We considered two GWAS of LDL cholesterol, HDL
cholesterol, TG and BMI from the Estonian Biobank at
the Estonian Genome Center, University of Tartu [18].
Individuals from the EGCUT-OMNI GWAS were geno-
typed with the Illumina HumanOmniExpress BeadChip,
whilst those from the EGCUT-370 GWAS were geno-
typed with the Illumina HumanCNV370 BeadChip. In
both studies, individuals were excluded on the basis of
call rate <95%, gender discordance with X chromosome
genotypes, and excess heterozygosity (>3 standard devia-
tions). After quality control 609 and 832 individuals,
respectively, were retained in EGCUT-OMNI and
EGCUT-370. SNPs were excluded on the basis of call
rate <95%, extreme deviation from Hardy-Weinberg
equilibrium (p <10−6), and MAF <1%. Principal compo-
nents were derived from a genetic related matrix in each
study to account for population structure in downstream
association analyses [19]. The genotype scaffold of indi-
viduals and SNPs passing quality control was pre-
phased, separately in each study, using SHAPEIT [20].
The phased scaffold was then imputed up to the 1000
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Genomes Project Consortium reference panel (all ances-
tries, June 2011 release) [21], separately in each study,
using IMPUTEv2 [15, 16]. SNPs with MAF <1% and im-
putation quality info score <0.4 were excluded from
downstream association analyses.
In both studies, HDL cholesterol, LDL cholesterol
and TG were measured from serum extracted from
whole blood. Lipid measurements deviating more than
5 standard deviations from the mean were set to miss-
ing. Individuals were excluded if they received lipid-
lowering medication at sample collection. The four
phenotypes were adjusted for age, age2 [2] and four
principal components to account for population struc-
ture. Residuals were calculated separately for men and
women, and inverse standard normal transformed by
the inverse standard normal function.
We applied SCOPA to the four phenotypes in each
GWAS, and aggregated association summary statistics
across studies using META-SCOPA. There was no evi-
dence for residual population structure within and be-
tween GWAS that was not accounted for in the
association analysis: λOMNI = 1.001 and λ370 = 0.999 for
EGCUT-OMNI and EGCUT-370, respectively, at the
study level, and λMA = 1.003 after meta-analysis.
Our META-SCOPA analysis revealed four loci
attaining genome-wide significant evidence of associ-
ation (p <5×10−8) with lipids and BMI (Figs. 1 and 2,
Table 1), mapping to/near: APOE (rs7412, p = 3.4×10−32);
CETP (rs56156922, p = 2.4×10−10); GPC5 (rs71427535, p =
1.1×10−8); and LIPC (rs2043085, p = 1.9×10−8). For com-
parison, we also performed univariate tests of association in
SCOPA for each phenotype, separately, within each GWAS,
and aggregated summary statistics across studies through
fixed-effects meta-analysis (inverse-variance weighting of
effect sizes) using GWAMA [22]. After correcting for test-
ing of four traits with Sidak’s adjustment, the signals of as-
sociation at each locus from SCOPA were always stronger
than observed in univariate analysis (Table 2).
The lead SNP at the APOE locus, rs7412, has been
previously reported, at genome-wide significance, in uni-
variate GWAS meta-analysis of lipid traits [23], where
the primary signal is with LDL cholesterol, but also with
strong associations with HDL cholesterol and TG. This
lead SNP is one of two tags that define APOE ε2/ε3/ε4
alleles [23]. Genetic variation at CETP and LIPC has also
been previously implicated in univariate GWAS meta-
analysis of lipid traits, where the primary associations
are with HDL cholesterol [2, 23, 24]. Our lead SNPs at
these loci are in strong linkage disequilibrium with those
previously reported [23] (r2 = 0.971 between rs56156922
and rs17231506 at CETP; r2 = 0.849 between rs2043085
and rs261291 at LIPC), suggesting that they represent
the same underlying association signals. The APOE locus
has also formerly been associated with BMI, at genome-
Fig. 1 Manhattan plot of META-SCOPA meta-analysis of GWAS of lipid traits and BMI in 1,441 individuals from the Estonian Genome Center, University
of Tartu. Each point represents a SNP passing quality control, plotted according to their genomic position (NCBI build GRCh37, UCSC hg19 assembly)
on the x-axis and their p-value for multiple phenotype association (on -log10 scale) on the y-axis. Previously reported loci for lipid traits and BMI are
highlighted in purple. Names of loci attaining genome-wide significance (p <5x10−8) are reported as the nearest gene to the lead SNP, unless a better
biological candidate maps nearby. SNPs attaining genome-wide significant, but not mapping to previously reported loci for lipid traits or BMI, are
highlighted in green
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Fig. 2 Signal plots for loci attaining genome-wide significance (p <5x10−8) from META-SCOPA meta-analysis of GWAS of lipid traits and BMI in
1,441 individuals from the Estonian Genome Center, University of Tartu. Each point represents a SNP passing quality control in the association
analysis, plotted with their p-value (on a -log10 scale) as a function of genomic position (NCBI build GRCh37, UCSC hg19 assembly). In each plot,
the lead SNP is represented by the purple symbol. The colour coding of all other variants indicates linkage disequilibrium with the lead SNP in
European ancestry haplotypes from the 1000 Genomes Project reference panel: red r2≥0.8; gold 0.6≤ r2 <0.8; green 0.4≤ r2 <0.6; cyan 0.2≤ r2 <0.4;
blue r2 <0.2; grey r2 unknown. Recombination rates are estimated from Phase II HapMap and gene annotations are taken from the University of
California Santa Cruz genome browser
Table 1 Loci attaining genome-wide significance (p <5×10−8) in META-SCOPA meta-analysis of GWAS of lipid traits and BMI in 1,441
individuals from the Estonian Genome Center, University of Tartu
Locus Lead SNP Chr Positiona
(bp)
Alleles EAF META-SCOPA
Effect Other BMI effect (SE) HDL effect (SE) LDL effect (SE) TG effect (SE) p-value
APOE rs7412 19 45,412,079 T C 0.102 −0.017 (0.011) −0.046 (0.011) 0.129 (0.011) −0.078 (0.012) 3.4×10−32
CETP rs56156922 16 56,987,369 C T 0.308 −0.026 (0.017) −0.119 (0.018) 0.046 (0.017) −0.024 (0.019) 2.4×10−10
GPC5 rs71427535 13 92,826,439 C T 0.108 0.007 (0.011) 0.014 (0.012) 0.024 (0.011) −0.065 (0.012) 1.1×10−8
LIPC rs2043085 15 58,680,954 T C 0.343 −0.022 (0.019) −0.124 (0.020) 0.013 (0.019) −0.070 (0.020) 1.9×10−8
Chr: chromosome. SE: standard error. EAF: effect allele frequency
aPosition reported for NCBI build GRCh37 (UCSC hg19 assembly)
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wide significance, in univariate GWAS meta-analysis
[25, 26], although the lead SNP from SCOPA is inde-
pendent of that previously reported (r2 = 0.013 between
rs7412 and rs2075650), suggesting that this signal is
distinct from that identified for LDL cholesterol.
Genetic variation at the GPC5 locus has not been pre-
viously associated with lipid traits or BMI at genome-
wide significance. The lead SNP, rs71427535, maps to an
intron of GPC5 (Glypican 5), a gene that plays a role in
the control of cell division and growth regulation. The
gene is involved in retinoid and carbohydrate metabolic
processes, making it a highly plausible candidate gene
for lipid metabolism, although further replication of the
association signal in additional studies is required.
We dissected multiple phenotype association signals
for the lead SNPs at the four loci attaining genome-wide
significance after meta-analysis. We determined the best
subset of phenotypes according to the BIC across stud-
ies, which represents a trade off in overall model fit with
the number of parameters required (Table 3). At CETP
and LIPC, the phenotype subset with minimum BIC for
the lead SNPs included only HDL cholesterol. This
model is consistent with previous reports [2, 23] that the
primary associations at these loci are with HDL choles-
terol, and that GWAS signals for other lipids at these
lead SNPs are likely driven through mediated pleiotropy.
At GPC5, the phenotype subset with minimum BIC for
the lead SNP included only TG, suggesting that the pri-
mary association signal at this locus is driven by this
specific serum lipid trait. Finally, at APOE, the pheno-
type subset with minimum BIC for the lead SNP in-
cluded HDL cholesterol, LDL cholesterol and TG.
Previous reports have highlighted association signals
with multiple lipid traits at this locus [2, 23, 24]. Our
analyses suggest that the multiple phenotype associa-
tions are not entirely driven by correlation between
lipids and mediation through LDL cholesterol, but high-
light biological pleiotropy as a possible driving mechan-
ism. However, further dissection of this locus in larger
samples is required to confirm this assertion, and causal
relationships between these phenotypes cannot be estab-
lished without more detailed Mendelian randomisation
studies, for example.
Conclusions
The SCOPA and META-SCOPA software enable discov-
ery and dissection of multiple phenotype association sig-
nals through implementation of a powerful reverse
regression approach. Application of the software to two
GWAS of HDL and LDL cholesterol, TG and BMI
Table 2 Univariate GWAS meta-analysis of lipid traits and BMI at lead SNPs in 1,441 individuals from the Estonian Genome Center,
University of Tartu
Locus Lead SNP Chr Positiona (bp) Alleles BMI HDL LDL TG
Effect Other Effect (SE) p-value Effect (SE) p-value Effect (SE) p-value Effect (SE) p-value
APOE rs7412 19 45,412,079 T C −0.018
(0.011)
0.41 −0.015
(0.011)
0.55 0.107
(0.011)
1.9×10−23 −0.025
(0.011)
0.093
CETP rs56156922 16 56,987,369 C T −0.007
(0.017)
0.99 −0.105
(0.016)
6.1×10−10 0.040
(0.017)
0.062 0.032
(0.017)
0.19
GPC5 rs71427535 13 92,826,439 C T −0.003
(0.011)
1.0 0.038
(0.011)
0.0012 0.006
(0.011)
0.96 −0.063
(0.011)
1.3×10−8
LIPC rs2043085 15 58,680,954 T C −0.009
(0.019)
0.98 −0.093
(0.018)
6.5×10−7 −0.005
(0.018)
1.0 −0.019
(0.018)
0.74
Chr: chromosome. SE: standard error
aPosition reported for NCBI build GRCh37 (UCSC hg19 assembly)
Table 3 Dissection of multiple phenotype association signals
for lead SNPs from META-SCOPA meta-analysis of GWAS of lipid
traits and BMI in 1,441 individuals from the Estonian Genome
Center, University of Tartu
Model Difference in BIC from null model
APOE:
rs7412
CETP:
rs56156922
GPC5:
rs71427535
LIPC:
rs2043085
BMI 10.29 12.64 12.99 12.73
HDL 10.85 −28.53 0.06 −14.75
LDL −86.12 7.26 8.86 10.31
TG 7.18 9.36 −21.69 11.95
BMI + HDL 20.75 −17.41 13.01 −3.44
BMI + LDL −76.28 19.96 21.91 23.01
BMI + TG 17.67 21.95 −9.23 24.61
HDL + LDL −75.72 −21.24 9.37 −3.94
HDL + TG 14.04 −15.75 −10.66 −13.61
LDL + TG −105.91 18.66 −17.68 21.70
BMI + HDL + LDL −66.14 −10.18 22.26 7.25
BMI + HDL + TG 24.27 −4.57 1.50 −1.62
BMI + LDL + TG −95.35 31.31 −5.21 34.30
HDL + LDL + TG −108.01 −10.02 −5.82 −4.07
BMI + HDL + LDL + TG −97.59 1.25 6.33 7.94
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highlighted stronger association signals than univariate
phenotype analysis at established lipid and obesity loci.
The meta-analysis also revealed a novel signal of associ-
ation for triglycerides mapping to GPC5 (lead SNP
rs71427535, p = 1.1×10−8), which has not been reported
in previous GWAS of lipid traits. Dissection of the
APOE locus highlighted associations with LDL and HDL
cholesterol and TG, and suggested biological pleiotropy as
a likely driving mechanism for this multiple lipid signal.
Availability and requirements
Project name: SCOPA.
Availability: the SCOPA and META-SCOPA software,
documentation and tutorial can be found at: http://
www.geenivaramu.ee/en/tools/scopa.
Operating system(s): Linux.
Programming language: C++ (including files from the
ALGLIB project for statistical analysis and the TCLAP
project for command line argument parsing).
Any restrictions on use by academics: none.
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